COVID-19 vaccine from Anhui earns conditional approval
By Wang Xiaoyu |
chinadaily.com.cn |
Updated: 2022-03-02 17:20
Share
Share - WeChat
China has given conditional approval for a recombinant protein subunit COVID-19 vaccine developed by domestic company Anhui Zhifei Longcom Biopharmaceutical, the National Medical Products Administration said on Wednesday.
The vaccine uses purified pieces of the virus' protein to trigger an immune response. It is the first vaccine based on this technology to be approved by the top drug regulator.
In total, five COVID-19 vaccines have been approved for public use in China so far.
- Intl scholars gather in Guilin for high-level academic exchange
- Yunnan leads the nation in solved drug cases, user population hits 20-year low
- Guangzhou launches new all-in-one visitor service platform
- Lhasa expands AI-powered smart growing containers in high-altitude district
- ASEAN-China short video contest awards ceremony held in Nanning
- China's Juncao technology to industrialize in Democratic Republic of the Congo
